A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Clinical trial NCT07221227 · RECRUITING

Trial details

NCT number: NCT07221227
Sponsor: GlaxoSmithKline
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-alcoholic Fatty Liver Disease

Start date: 2025-10-24
Primary completion: 2028-03-29
Enrollment: 1200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.